Cited by 202Blood Pressure and Hypertension StudiesCardiovascular Health and Disease PreventionNon-Invasive Vital Sign Monitoring

Ambulatory blood pressure monitoring in children and adolescents: 2022 update: a scientific statement from the American Heart Association

Flynn, Joseph T., Urbina, Elaine M., Brady, Tammy M., Baker-Smith, Carissa, Daniels, Stephen R., Hayman, Laura L., Mitsnefes, Mark, Tran, Andrew +2 more·2022·Hypertension

Abstract

Use of ambulatory blood pressure monitoring in children and adolescents has markedly increased since publication of the last American Heart Association scientific statement on pediatric ambulatory blood pressure monitoring in 2014. In addition, there has also been significant expansion of the evidence base for use of ambulatory blood pressure monitoring in the pediatric population, including new data linking ambulatory blood pressure levels with the development of blood pressure–related target organ damage. Last, additional data have recently been published that enable simplification of the classification of pediatric ambulatory monitoring studies. This scientific statement presents a succinct review of this new evidence, guidance on optimal application of ambulatory blood pressure monitoring in the clinical setting, and an updated classification scheme for the interpretation of ambulatory blood pressure monitoring in children and adolescents. We also highlight areas of uncertainty where additional research is needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/hyp.0000000000000215

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Studies of 'metabolically healthy obesity' have found that over 4 to 5 years of follow-up, approximately 30% to 45% develop metabolic syndrome or diabetes.

    “Studies of”

    From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]

    The cardiovascular-risk section discusses how childhood blood pressure relates to later cardiovascular outcomes, and the obesity-related passages concern ambulatory blood pressure. Searches for “metabolically healthy obesity,” “metabolic syndrome,” and the claimed 30%–45% transition over 4–5 years found no passage addressing that finding. (LLM, conf=0.75)

    Experimental — accuracy not yet measured
  • Several studies found that GLP-1-based therapies would not be cost-effective compared with usual care, especially when used as first-line therapy.

    “In general, these studies found that GLP-1–based therapies would not be cost-effective compared with usual care, especially when used as first-line therapy.”

    From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]

    The cited paper’s ‘Conclusions and Future Directions’ discusses ambulatory blood pressure monitoring in young people, not the cost-effectiveness of drug therapies. Searches for GLP-1 therapies, cost-effectiveness, usual care, and first-line therapy found no passage addressing the claim; the paper’s References section does not establish it either. Page numbers were not available in our copy. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • SGLT2i appear to primarily reduce incident and worsening HF.

    “SGLT2i appear to primarily reduce incident and worsening HF.17,37–44”

    From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]

    The cited statement’s Cardiovascular Risk in the Pediatric Population section discusses childhood blood pressure and later cardiovascular disease, not the effects of SGLT2 inhibitors. Searches of our copy for “SGLT2i,” sodium-glucose cotransporter 2 inhibitors, and incident or worsening heart failure found no passage addressing the claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • Based on results across finerenone trials, finerenone likely confers both cardiovascular and kidney benefits in those with albuminuric DKD and HFmrEF/HFpEF.

    “Based on the results across these trials, it is likely that finerenone confers both cardiovascular and kidney benefits in those with albuminuric DKD and HFmrEF/HFpEF, though a more dedicated study of this population is needed.”

    From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]

    The ‘Usefulness in Chronic Conditions’ section discusses ambulatory blood-pressure patterns in children with conditions including CKD and diabetes, not finerenone treatment. Searches for finerenone and for HFmrEF/HFpEF found no passage in our copy addressing cardiovascular or kidney benefits in the claimed population. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • In FINEARTS-HF alone, finerenone did not result in a reduction in the primary kidney endpoint.

    “in FINEARTS-HF alone, finerenone did not result in a reduction in the primary kidney endpoint.44”

    From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]

    The cited paper discusses ambulatory blood pressure monitoring in children and adolescents; the relevant passages returned are in its References section (page unavailable). Searches for FINEARTS-HF, finerenone, and a primary kidney endpoint found no passage addressing the trial or its result. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Flynn, J. T., Urbina, E. M., Brady, T. M., Baker-Smith, C., Daniels, S. R., Hayman, L. L., Mitsnefes, M., Tran, A., Zachariah, J. P., & on behalf of the Atherosclerosis, H.
Venue
Hypertension
Published
2022-07
Volume
79
Issue
7
Pages
e114-e124
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
OpenAlex
W4281298204
Cited by
202
References
57
Citations by year
2026: 61 · 2025: 50 · 2024: 42 · 2023: 38 · 2022: 11
FWCI
7.17
Type
journal article
Language
en
Open access
closed
Locations
  • Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (R01HL148217)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Physical Sciences › Engineering › Biomedical Engineering › Non-Invasive Vital Sign Monitoring
Keywords
ambulatory blood pressure monitoring, pediatric hypertension, children and adolescents, target organ damage, blood pressure classification, hypertension diagnosis
MeSH terms
Adolescent, American Heart Association, Blood Pressure, Child, Humans, Hypertension, United States, Blood Pressure Monitoring, Ambulatory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review